Dilip Shanghvi

Last Updated on August 24, 2020

Dilip Shanghvi  is an Indian billionaire businessman and one of the country’s richest people. He founded Sun Pharmaceuticals. The Government of India awarded him the civilian honour of the Padma Shri in 2016. India Today magazine ranked him 8th in India’s most powerful people of 2017 list

According to Forbes, as of October 2019, Shanghvi is the 12th richest person in India with a net worth of US$6.9 billion

Dilip Shanghvi displaces Mukesh Ambani as India's richest person
Born1 October 1955 (age 64)
Amreli, Gujarat, India
Alma materBhawanipur Education Society College, University of Calcutta
OccupationFounder and MD of Sun Pharmaceuticals
Net worthUS$6.9 billion (October 2019
Spouse(s)Vibha Shanghvi

Early life

Dilip Shanghvi hails from a Jain family who was born in the small town of Amreli in Gujarat to Shantilal Shanghvi and Kumud Shanghvi Shanghvi earned a Bachelor of Commerce degree from the University of Calcutta.. He spent his childhood and college life with his parents in the Burrabazar locality of Calcutta. He is an alumnus of J. J. Ajmera High School and Bhawanipur Education Society College, where he did his schooling and graduation, respectively.


He started by helping his father in his wholesale generic drugs business in Kolkata.It was during this work that he thought of manufacturing his own drugs instead of selling others’ products.

Dilip Shanghvi is the founder of $3.6billion, Sun Pharma, India's ...

Shanghvi started Sun Pharmaceutical Industries with capital of INR 10,000 in 1982 at Vapi, with one psychiatry drug In 1997, Sun acquired Caraco Pharma, a loss-making American company, with the aim of expanding Sun’s reach in the United States.[citation needed] Sun also acquired Israel’s Taro Pharma in 2007 Shanghvi stepped down as chairman and CEO in 2012 and chose Israel Makov, formerly CEO of Teva Pharmaceuticals, as his successor; Shanghvi became managing director In April 2014 Sun, Ranbaxy, and Daiichi Sankyo (the majority shareholder in Ranbaxy) agreed that Sun would acquire all outstanding shares of Ranbaxy for $3.2 billion in Sun stock and that Sun would take on $800M in Ranbaxy debt; the deal closed in March 2015 and made Sun the largest drug company in India and fifth largest in the world, and made Daiichi the second largest shareholder in Sun.


In January 2018, the Indian government appointed Shanghvi to the Reserve Bank of India’s 21-member central board committee.[13] He is chairman of the board of governors at IIT Bombay. He was made a trustee of the Rhodes scholarship programme at Oxford University in 2017.

Personal life

He is married to Vibha Shanghvi. They have a son, Aalok and a daughter, Vidhi, both of whom work for Sun Pharmaceuticals.

Sun Pharma: Dilip Shanghvi's daughter Vidhi to head consumer ...


In 2019, journalist Soma Das authored The Reluctant Billionaire, the first and only biography of Dilip Shanghvi. Published by Penguin Random House, the book was nominated for Tata Literature Award in the Best Business Book category in November 2019